{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:09:21Z","timestamp":1780117761139,"version":"3.54.0"},"reference-count":72,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly inherited kidney disease. In the absence of targeted therapies, it invariably progresses to advanced chronic kidney disease. To date, the only approved treatment is tolvaptan, a vasopressin V2 receptor antagonist that has been demonstrated to reduce cyst growth and attenuate the decline in kidney function. However, it has various side effects, the most frequent of which is aquaresis, leading to a significant discontinuation rate. The strategies proposed to combat aquaresis include the use of thiazides or metformin and a reduction in the dietary osmotic load. Beyond the prescription of tolvaptan, which is limited to those with a rapid and progressive decline in kidney function, dietary interventions have been suggested to protect against disease progression. Moderate sodium restriction, moderate protein intake (up to 0.8 g\/kg\/day), avoidance of being overweight, and increased water consumption are recommended in ADPKD guidelines, though all with low-grade evidence. The aim of the present review is to critically summarize the evidence on the effect of dietary modification on ADPKD and to offer some strategies to mitigate the adverse aquaretic effects of tolvaptan.<\/jats:p>","DOI":"10.3390\/nu14214651","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T04:00:51Z","timestamp":1667534451000},"page":"4651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-1929","authenticated-orcid":false,"given":"Borja","family":"Quiroga","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[{"name":"Inherited Kidney Disorders, Department of Nephrology, Fundaci\u00f3 Puigvert, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB-SANT PAU), Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"ref_1","unstructured":"(2022, September 01). PKD Foundation. Available online: www.pkdcure.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2011.02.379","article-title":"Hypertension and Autosomal Dominant Polycystic Kidney Disease","volume":"57","author":"Schrier","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of Dietary Sodium Potentiates the Renal and Cardiovascular Protective Effects of Angiotensin Receptor Blockers","volume":"82","author":"Holtkamp","year":"2012","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium Intake, ACE Inhibition, and Progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.1956","article-title":"ACE Inhibition Has Adverse Renal Effects during Dietary Sodium Restriction in Proteinuric and Healthy Rats","volume":"209","author":"Hamming","year":"2006","journal-title":"J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(97)26036-8","article-title":"Ramipril in Non-Diabetic Renal Failure (REIN Study). Ramipril Efficiency in Nephropathy Study","volume":"350","author":"Schweda","year":"1997","journal-title":"Lancet Lond. Engl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2215\/CJN.04260415","article-title":"Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings","volume":"10","author":"Denker","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but Not Protein Intake, Is Associated with Accelerated Disease Progression in Autosomal Dominant Polycystic Kidney Disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary Salt Restriction Is Beneficial to the Management of Autosomal Dominant Polycystic Kidney Disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney Disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease","volume":"371","author":"Torres","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"key":"ref_18","unstructured":"WHO (2022, September 01). Guideline: Sodium Intake for Adults and Children. Available online: http:\/\/apps.who.int\/iris\/handle\/10665\/77985."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00614.2014","article-title":"Protein- and Diabetes-Induced Glomerular Hyperfiltration: Role of Glucagon, Vasopressin, and Urea","volume":"309","author":"Bankir","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2013). Summary of Recommendation Statements. Kidney Int. Suppl., 3, 5\u201314.","DOI":"10.1038\/kisup.2012.77"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary Protein Restriction, Blood Pressure Control, and the Progression of Polycystic Kidney Disease. Modification of Diet in Renal Disease Study Group","volume":"5","author":"Klahr","year":"1995","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1681\/ASN.V102300","article-title":"Dietary Soy Protein Effects on Inherited Polycystic Kidney Disease Are Influenced by Gender and Protein Level","volume":"10","author":"Aukema","year":"1999","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.1992.358","article-title":"Effects of Dietary Protein Restriction and Oil Type on the Early Progression of Murine Polycystic Kidney Disease","volume":"42","author":"Aukema","year":"1992","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-Dominant Polycystic Kidney Disease (ADPKD): Executive Summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int."},{"key":"ref_25","first-page":"872","article-title":"Arterial lipiodol chemoembolization of a left liver metastasis through the right internal thoracic artery","volume":"80","author":"Mignon","year":"1999","journal-title":"J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.semnephrol.2015.10.008","article-title":"KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management","volume":"35","author":"Campbell","year":"2015","journal-title":"Semin. Nephrol."},{"key":"ref_27","unstructured":"(2022, September 01). World Health Orgamization, Guidelines on Protein and Aminoacid Requirements in Human Nutrition. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43411\/who_trs_935_eng.pdf?sequence=1."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food Restriction Ameliorates the Development of Polycystic Kidney Disease","volume":"27","author":"Warner","year":"2016","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev.biochem.77.061206.171059","article-title":"Aging and Survival: The Genetics of Life Span Extension by Dietary Restriction","volume":"77","author":"Mair","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1126\/science.273.5271.59","article-title":"Oxidative Stress, Caloric Restriction, and Aging","volume":"273","author":"Sohal","year":"1996","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A Mild Reduction of Food Intake Slows Disease Progression in an Orthologous Mouse Model of Polycystic Kidney Disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic Reprogramming and the Role of Mitochondria in Polycystic Kidney Disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12967-019-2104-z","article-title":"The Management of Very Low-Calorie Ketogenic Diet in Obesity Outpatient Clinic: A Practical Guide","volume":"17","author":"Muscogiuri","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/ckj\/sfab162","article-title":"Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease-a Retrospective Case Series Study: First Insights into Feasibility, Safety and Effects","volume":"15","author":"Strubl","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ckj\/sfac103","article-title":"Can Ketogenic Dietary Interventions Slow Disease Progression in ADPKD: What We Know and What We Don\u2019t","volume":"15","author":"Ong","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.jrn.2017.06.005","article-title":"The Myth of Water and Salt: From Aquaretics to Tenapanor","volume":"28","author":"Visconti","year":"2018","journal-title":"J. Ren. Nutr."},{"key":"ref_39","first-page":"1710","article-title":"Does Increased Water Intake Prevent Disease Progression in Autosomal Dominant Polycystic Kidney Disease?","volume":"29","author":"Higashihara","year":"2014","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/qjmed\/hcz278","article-title":"High Water vs. Ad Libitum Water Intake for Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Feasibility Trial","volume":"113","author":"Lee","year":"2020","journal-title":"QJM Mon. J. Assoc. Physicians"},{"key":"ref_41","first-page":"e022859","article-title":"Randomised Controlled Trial of High versus Ad Libitum Water Intake in Patients with Autosomal Dominant Polycystic Kidney Disease: Rationale and Design of the DRINK Feasibility Trial","volume":"8","author":"Lee","year":"2018","journal-title":"BMJ Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised Controlled Trial to Determine the Efficacy and Safety of Prescribed Water Intake to Prevent Kidney Failure Due to Autosomal Dominant Polycystic Kidney Disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40620-018-0470-x","article-title":"Nutritional therapy in autosomal dominant polycystic kidney disease","volume":"31","author":"Cupisti","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"McKenzie, K.A., El Ters, M., Torres, V.E., Harris, P.C., Chapman, A.B., Mrug, M., Rahbari-Oskoui, F.F., Bae, K.T., Landsittel, D.P., and Bennett, W.M. (2018). Relationship between Caffeine Intake and Autosomal Dominant Polycystic Kidney Disease Progression: A Retrospective Analysis Using the CRISP Cohort. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1182-0"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","article-title":"Long-Term Effect of Coffee Consumption on Autosomal Dominant Polycystic Kidneys Disease Progression: Results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study","volume":"31","author":"Puhan","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Carriazo, S., Perez-Gomez, M.V., Cordido, A., Garc\u00eda-Gonz\u00e1lez, M.A., Sanz, A.B., Ortiz, A., and Sanchez-Ni\u00f1o, M.D. (2019). Dietary Care for ADPKD Patients: Current Status and Future Directions. Nutrients, 11.","DOI":"10.3390\/nu11071576"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cupisti, A., D\u2019Alessandro, C., Gesualdo, L., Cosola, C., Gallieni, M., Egidi, M.F., and Fusaro, M. (2017). Non-Traditional Aspects of Renal Diets: Focus on Fiber, Alkali and Vitamin K1 Intake. Nutrients, 9.","DOI":"10.3390\/nu9050444"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MNH.0000000000000734","article-title":"Emerging Non-Pharmacological Interventions in ADPKD: An Update on Dietary Advices for Clinical Practice","volume":"30","author":"Meijer","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_49","first-page":"477","article-title":"TEMPO 4:4 Trial Investigators Multicenter, Open-Label, Extension Trial to Evaluate the Long-Term Efficacy and Safety of Early versus Delayed Treatment with Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: The TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2215\/CJN.10250620","article-title":"Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"16","author":"Torres","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Not yet on Dialysis","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Neijenhuis, M.K., Kievit, W., Perrone, R.D., Sloan, J.A., Erwin, P., Murad, M.H., Gevers, T.J.G., Hogan, M.C., and Drenth, J.P.H. (2017). The Effect of Disease Severity Markers on Quality of Life in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review, Meta-Analysis and Meta-Regression. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0578-6"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Suwabe, T., Ubara, Y., Mise, K., Kawada, M., Hamanoue, S., Sumida, K., Hayami, N., Hoshino, J., Hiramatsu, R., and Yamanouchi, M. (2013). Quality of Life of Patients with ADPKD-Toranomon PKD QOL Study: Cross-Sectional Study. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-179"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/ckj\/sfaa259","article-title":"Developing a Patient-Centred Tool for Pain Measurement and Evaluation in Autosomal Dominant Polycystic Kidney Disease","volume":"14","author":"Lee","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100415","DOI":"10.1016\/j.xkme.2022.100415","article-title":"Polycystic Kidney Disease\u2013Related Disease Burden in Adolescents with Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study","volume":"4","author":"Oberdhan","year":"2022","journal-title":"Kidney Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Joly, D., Quinn, J., Mokiou, S., O\u2019Reilly, K., S\u00e1nchez-Covisa, J., Wang-Silvanto, J., and Doll, H. (2020). Rationale and Study Protocol of ACQUIRE, a Prospective, Observational Study Measuring Quality of Life, Treatment Preference and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients in Europe. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-01927-1"},{"key":"ref_58","first-page":"29","article-title":"The RAND Kidney Disease and Quality of Life Instrument","volume":"9","author":"Kallich","year":"1995","journal-title":"Nephrol. News Issues"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.xkme.2019.11.008","article-title":"Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan","volume":"2","author":"Anderegg","year":"2020","journal-title":"Kidney Med."},{"key":"ref_60","first-page":"e25045","article-title":"The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life","volume":"14","author":"Tarabzuni","year":"2022","journal-title":"Cureus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/1570161118999200918094809","article-title":"Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy with Tolvaptan: A Pilot Study","volume":"19","author":"Lai","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lu, J., Xu, W., Gong, L., Xu, M., Tang, W., Jiang, W., Xie, F., Ding, L., and Qian, X. (2022). Efficacy and Safety of Tolvaptan versus Placebo in the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis. Int. Urol. Nephrol.","DOI":"10.1007\/s11255-022-03353-8"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"gfaa139.SO002","DOI":"10.1093\/ndt\/gfaa139.SO002","article-title":"SO002 Interim Results from Acquire: A Study Measuring Quality of Life, Treatment Preference and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease Patients in Europe","volume":"35","author":"Joly","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","article-title":"The Effect of Trichlormethiazide in Autosomal Dominant Polycystic Kidney Disease Patients Receiving Tolvaptan: A Randomized Crossover Controlled Trial","volume":"11","author":"Uchiyama","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_66","first-page":"1828","article-title":"DIPAK Consortium Thiazide Diuretics and the Rate of Disease Progression in Autosomal Dominant Polycystic Kidney Disease: An Observational Study","volume":"36","author":"Kramers","year":"2021","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","article-title":"The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations","volume":"5","author":"Perrone","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ekir.2020.03.013","article-title":"A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD","volume":"5","author":"Perrone","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_69","first-page":"693","article-title":"Doctor, How Much Should I Drink?","volume":"34","author":"Lorenzo","year":"2014","journal-title":"Nefrol. Publ. Soc. Espanola Nefrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nefro.2021.05.009","article-title":"Documento de consenso de poliquistosis renal autos\u00f3mica dominante del grupo de trabajo de enfermedades hereditarias de la Sociedad Espa\u00f1ola de Nefrolog\u00eda. Revisi\u00f3n 2020","volume":"42","author":"Ars","year":"2022","journal-title":"Nefrolog\u00eda"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000177975","article-title":"Coffee Consumption and Total Body Water Homeostasis as Measured by Fluid Balance and Bioelectrical Impedance Analysis","volume":"41","author":"Beine","year":"1997","journal-title":"Ann. Nutr. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMra1816604","article-title":"Coffee, Caffeine, and Health","volume":"383","author":"Hu","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/21\/4651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:10:05Z","timestamp":1760145005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/21\/4651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":72,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["nu14214651"],"URL":"https:\/\/doi.org\/10.3390\/nu14214651","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}